J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Overall, this suggests that the cumulative risk of breast cancer before age 55 for women taking estrogen/progestin is about 4 ...

Hot flashes are a menopausal hallmark: Up to 80 percent of women have them. But numerous lesser-known symptoms are also ...

A new study led by researchers at Penn State College of Medicine suggests that long-term use of estrogen-based hormone ...

How long hot flashes last, hormone replacement therapy as the only option to treat symptoms and when menopause starts are ...

Breast cancer survivors treated with radiation therapy have an 8% lower risk of developing Alzheimer’s disease, albeit only ...

Just over two weeks after the Supreme Court upheld Tennessee’s ban on the use of puberty blockers and hormone therapy for ...

Women working permanent night shifts vs. day shifts faced an elevated likelihood for moderate to severe asthma, whereas this ...

Testosterone boosters are gaining popularity among men seeking to regain strength, energy, and libido. These supplements ...

The study, published Tuesday in The Lancet Oncology, focused on women under 55 with and without a uterus. CBS News medical ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Get CBS19 news on-demand by downloading the free CBS19+ app available on ROKU, Amazon Fire and Apple TV!